Payment overview · 2025
General Payments
$512.88
25 reported records · 16 companies
Healthcare provider profile · identity verified
Jehan Pascal Murugaser, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CAPE GIRARDEAU, MO · NPI 1093074932
Verified facts
What the public records show
CMS Open Payments records show Jehan Pascal Murugaser, M.D. received $512.88 in general payments during 2025 across 25 reported records.
ABBVIE INC. accounted for 12.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.87 | 12.3% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $60.63 | 11.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.60 | 10.4% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $42.89 | 8.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.70 | 7.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.92 | 7.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.02 | 6.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.77 | 6.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.65 | 4.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.44 | 4.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $20.03 | 3.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.74 | 3.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.67 | 3.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.75 | 3.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.25 | 3.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.95 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $475.18 | 23 |
| Education | $37.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Encore Normalized: encore |
Device | Philips North America LLC | $60.63 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $53.60 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $53.60 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $42.89 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.92 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $34.02 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $34.02 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.02 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.77 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.85 | 1 | 2025 |
Source payment records
|
|||||
| ALINITY M Normalized: alinity m |
Device | Abbott Laboratories | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 80 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 754 | 184 |
| Amlodipine Besylate | Amlodipine Besylate | 594 | 134 |
| Lisinopril | Lisinopril | 555 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 406 | 86 |
| Gabapentin | Gabapentin | 387 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 370 | 85 |
| Losartan Potassium | Losartan Potassium | 359 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 293 | 66 |
| Omeprazole | Omeprazole | 283 | 63 |
| Metformin Hcl | Metformin Hcl | 261 | 65 |
| Meloxicam | Meloxicam | 210 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 48 |
| Montelukast Sodium | Montelukast Sodium | 203 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 200 | 50 |
| Metformin Hcl Er | Metformin Hcl | 195 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 168 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 44 |
| Trazodone Hcl | Trazodone Hcl | 149 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 33 |
| Clonazepam | Clonazepam | 137 | 25 |
| Furosemide | Furosemide | 135 | 36 |
| Carvedilol | Carvedilol | 130 | 29 |
| Allopurinol | Allopurinol | 121 | 26 |
| Sertraline Hcl | Sertraline Hcl | 117 | 27 |
| Potassium Chloride | Potassium Chloride | 116 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 26 |
| Simvastatin | Simvastatin | 107 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 27 |
| Chlorthalidone | Chlorthalidone | 83 | 23 |
| Ozempic | Semaglutide | 83 | 14 |
| Jardiance | Empagliflozin | 80 | 17 |
| Temazepam | Temazepam | 80 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 18 |
| Alendronate Sodium | Alendronate Sodium | 73 | 14 |
| Pregabalin | Pregabalin | 73 | 18 |
| Buspirone Hcl | Buspirone Hcl | 71 | 20 |
| Celecoxib | Celecoxib | 67 | suppressed |
| Lovastatin | Lovastatin | 67 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 16 |
| Tramadol Hcl | Tramadol Hcl | 66 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 20 |
| Spironolactone | Spironolactone | 62 | 21 |
| Eliquis | Apixaban | 60 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 60 | suppressed |
| Xarelto | Rivaroxaban | 59 | 13 |
| Ezetimibe | Ezetimibe | 57 | 19 |
| Alprazolam | Alprazolam | 54 | suppressed |
| Bupropion Xl | Bupropion Hcl | 54 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 53 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Lorazepam | Lorazepam | 53 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 15 |
| Trulicity | Dulaglutide | 52 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 51 | 12 |
| Memantine Hcl | Memantine Hcl | 51 | 12 |
| Glipizide | Glipizide | 49 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | suppressed |
| Indapamide | Indapamide | 48 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | suppressed |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 45 | suppressed |
| Januvia | Sitagliptin Phosphate | 45 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 17 |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Vascepa | Icosapent Ethyl | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 13 |
| Propranolol Hcl | Propranolol Hcl | 34 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 26 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $512.88 · 25 records | ABBVIE INC. | ALINITY M, BEXSERO, BREZTRI, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, Encore, JARDIANCE, Kerendia, LEQVIO, LINZESS, MOUNJARO, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, VOQUEZNA, YUPELRI | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error